Jones Kristin C
Menninger Department of Psychiatry and Behavioral Sciences, Baylor College of Medicine, Houston.
Focus (Am Psychiatr Publ). 2021 Jul;19(3):271-281. doi: 10.1176/appi.focus.20210004. Epub 2021 Jul 9.
Dementia is a syndrome characterized by a gradually progressive course that spans a continuum from preclinical symptoms to major impairment in two or more cognitive domains with functional decline. In this review, the author examines some of the more common dementia syndromes from among dozens of different diseases. Findings show that as the U.S. population continues to age, the number of Americans with dementia is expected to rise drastically over the next several decades. This upsurge will contribute to increased health care costs and will have a significant public health impact. Neurodegenerative disorders such as Alzheimer's disease, frontotemporal degeneration, and alpha-synucleinopathies (e.g., Lewy body disease and Parkinson's disease) are some of the more prevalent causes for dementia. In recent years, advancements in neuroimaging, understanding of genetic contributions and pathological changes, and the development of novel biomarkers have fueled clinical understanding of these disorders. However, substantial disease-modifying therapies are still lagging. The advent of future interventions hinges on the ability to discern the distinct clinico-pathologic profiles of the various dementia syndromes and to identify reliable biomarkers for utilization in clinical trials.
痴呆是一种综合征,其特征是病程逐渐进展,涵盖从临床前症状到两个或更多认知领域出现重大损害并伴有功能衰退的连续过程。在本综述中,作者研究了几十种不同疾病中一些较为常见的痴呆综合征。研究结果表明,随着美国人口持续老龄化,预计在未来几十年里,美国痴呆患者的数量将急剧上升。这种激增将导致医疗保健成本增加,并对公共卫生产生重大影响。神经退行性疾病,如阿尔茨海默病、额颞叶变性和α-突触核蛋白病(如路易体病和帕金森病)是痴呆的一些更常见病因。近年来,神经影像学的进展、对基因贡献和病理变化的认识以及新型生物标志物的开发,推动了对这些疾病的临床理解。然而,实质性的疾病修正疗法仍然滞后。未来干预措施的出现取决于能否辨别各种痴呆综合征独特的临床病理特征,并确定可靠的生物标志物以用于临床试验。